Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Pre-Market Trading 11-26 06:21:40 EST

12.46

-0.07

-0.56%

High12.94	Low12.41	Vol7.90M
Open12.71	D1 Closing12.53	Amplitude4.19%
Mkt Cap9.07B	Tradable Cap4.63B	Total Shares727.95M
T/O99.24M	T/O Rate2.13%	Tradable Shares371.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":12.46,"timestamp":1732568400000,"preClose":12.53,"halted":0,"volume":7904743,"delay":0,"floatShares":371772087,"shares":727949744,"eps":5.886067,"marketStatus":"Pre-Market Trading","change":-0.07,"latestTime":"11-26 06:21:40 EST","open":12.71,"high":12.935,"low":12.41,"amount":99239613.804177,"amplitude":0.041899,"askPrice":12.5,"askSize":40,"bidPrice":11.76,"bidSize":850,"shortable":3,"etf":0,"ttmEps":5.886067,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732631400000},"marketStatusCode":1,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":12.46,"postHourTrading":{"tag":"盘后","latestPrice":12.3019,"preClose":12.46,"latestTime":"18:55 EST","volume":470591,"amount":5863713.777,"timestamp":1732578946612},"volumeRatio":1.302937706644562,"optionData":{"bulkOrders":[{"symbol":"ROIV","call":true,"expireDate":1734670800000,"strike":"13.0","timestamp":1732546853829,"price":0.3,"volume":1275,"amount":38250,"type":"+"}]},"impliedVol":0.2989,"impliedVolPercentile":0.3532},"requestUrl":"/m/hq/s/ROIV/wiki","defaultTab":"wiki","newsList":[{"id":"2486523890","title":"Vertex leads J.P. Morgan's top biotech picks list for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2486523890","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486523890?lang=en_us&edition=fundamental","pubTime":"2024-11-26 04:10","pubTimestamp":1732565416,"startTime":"0","endTime":"0","summary":"DNY59 J.P. Morgan said its top biotech picks for 2025 were Vertex (NASDAQ:VRTX), Travere (NASDAQ:TVTX), SpringWorks (NASDAQ:SWTX), PTC Therapeutics (NASDAQ:PTCT), Wave Life Sciences (NASDAQ:WVE), Xeno","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/483098985/image_483098985.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/483098985/image_483098985.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4331812-vertex-leads-jp-morgans-top-biotech-picks-list-for-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0109394709.USD","BK4567","LU0079474960.USD","EWTX","XENE","BK4585","LU0256863811.USD","LU1093756168.USD","LU0320765992.SGD","BK4007","IE00B19Z3581.USD","LU2237438978.USD","BK4139","LU0889565916.HKD","IE00B2B36J28.USD","LU2362540622.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","IE0002270589.USD","LU1069344957.HKD","LU0234570918.USD","LU2456880835.USD","SWTX","LU0053671581.USD","LU0061475181.USD","LU2362541513.USD","LU2462157665.USD","WVE","IE00BZ9MQY76.HKD","BK4533","LU1585245621.USD","IE00B19Z3B42.SGD","LU2362541273.HKD","VRTX","IE00BFTCPJ56.SGD","LU0417517546.SGD","BPMC","IE00BJT1NW94.SGD","LU1430594728.SGD","IMVT","PTCT","LU1093756325.SGD","TVTX","IE0009355771.USD","ROIV","LU1035775433.USD","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","IE00B894F039.SGD","BK4539"],"gpt_icon":0},{"id":"2485126771","title":"Musk, Ramaswamy plan to lean on Supreme Court rulings to reduce federal agencies reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2485126771","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485126771?lang=en_us&edition=fundamental","pubTime":"2024-11-21 02:46","pubTimestamp":1732128362,"startTime":"0","endTime":"0","summary":"Nov 20 (Reuters) - Elon Musk's government efficiency panel said in a Wall Street Journal opinion story on Wednesday that they will apply recent Supreme Court rulings that can be used to take power awa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0316494557.USD","LU1551013425.SGD","LU1861558580.USD","LU1914381329.SGD","SG9999015945.SGD","LU1435385759.SGD","BK4139","LU0943347566.SGD","LU1429558221.USD","LU2249611893.SGD","LU1861559042.SGD","BK4592","LU0820561818.USD","LU0823414478.USD","LU1629891620.HKD","BK4516","LU2756315664.SGD","TSLA","IE00BSNM7G36.USD","LU2326559502.SGD","LU2087621335.USD","BK4588","BK4548","LU0097036916.USD","LU0823411888.USD","LU0198837287.USD","LU2023250330.USD","LU1852331112.SGD","LU2213496289.HKD","LU1861215975.USD","BK4527","IE00BJLML261.HKD","LU2602419157.SGD","LU0689472784.USD","BK4581","LU0820561909.HKD","SG9999015978.USD","ROIV","SG9999015952.SGD","LU1145028129.USD","LU0234572021.USD","LU0719512351.SGD","LU0234570918.USD","LU0082616367.USD","BK4533","LU1720051017.SGD","BK4007","LU2756315318.SGD","BK4555","BK4598"],"gpt_icon":1},{"id":"2484924507","title":"JPMorgan’s ‘Analyst Focus List’ – growth, income, value, short ideas","url":"https://stock-news.laohu8.com/highlight/detail?id=2484924507","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484924507?lang=en_us&edition=fundamental","pubTime":"2024-11-20 00:06","pubTimestamp":1732032406,"startTime":"0","endTime":"0","summary":"Sean Anthony Eddy/E+ via Getty Images J.P. Morgan analysts updated their “Analyst Focus List,” adding Tapestry (TPR), Alarm.com (ALRM), Regency Centers (REG), and Travere (TVTX). This is a list of sto","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1706156497/image_1706156497.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1706156497/image_1706156497.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4307534-jpmorgans-analyst-focus-list-growth-income-value-short-ideas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["ARMK","TMUS","AGCO","AMZN","VST","CYBR","TRGP","TRU.AU","AXL","TFII","TRU","GWRE","ANF","AXL.AU","BBY","XENE","ULTA","ACI","JPM","ROIV","SPGI","PODD","NOW","BSX","CAT.AU","REG.AU","GM","RCL.AU","CAT","ELF","LNG","TMO","CZR.AU","PVH","LLY","SCHW","DD","LOW","NTRA","UAL","NLY","PHM","BRBR","T","ALL","EWTX","TJX","TVTX","ALRM"],"gpt_icon":1},{"id":"2484091797","title":"Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution","url":"https://stock-news.laohu8.com/highlight/detail?id=2484091797","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484091797?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:05","pubTimestamp":1732014353,"startTime":"0","endTime":"0","summary":"The latest earnings release from Roivant Sciences Ltd.  disappointed investors. We did some analysis and believe that they might be concerned about some weak underlying factors.Check out our latest analysis for Roivant Sciences. NasdaqGS:ROIV Earnings and Revenue History November 19th 2024. Given the accrual ratio, it's not overly surprising that Roivant Sciences' profit was boosted by unusual items worth US$5.5b in the last twelve months. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. Roivant Sciences had a rather significant contribution from unusual items relative to its profit to September 2024. As","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roivant-sciences-nasdaq-roiv-shareholders-110553273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ROIV","NDAQ",".IXIC"],"gpt_icon":0},{"id":"2483056543","title":"Defense Stocks Don't Have to Fear Elon Musk, Pete Hegseth, and the $600 Hammer -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2483056543","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483056543?lang=en_us&edition=fundamental","pubTime":"2024-11-15 23:44","pubTimestamp":1731685440,"startTime":"0","endTime":"0","summary":"Investors are wondering what is next for defense stocks after a swift two-day decline triggered by rising uncertainty.Three things are weighing on investors' minds. For starters, Tuesday's nomination of Pete Hegseth as defense secretary surprised Wall Street. That was followed by a Thursday report from Reuters that indicated the coming Trump administration plans significant turnover at the Defense Department.Topping things off is the newly created Department of Government Efficiency, headed by Tesla CEO Elon Musk and Roivant Sciences founder Vivek Ramaswamy. They are tasked with reducing wasteful government spending, and no one knows how that will affect the defense sector.It was a lot for investors to digest in a short time. Shares of large defense contractors Lockheed Martin, General Dynamics, Northrop Grumman, and L3Harris Technologies fell 5.5% on average between Tuesday and Thursday. The iShares Aerospace & Defense ETF fell 1.9%.\"The period 2010 to 2013 is likely the timeframe mos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LMT","LU0320765646.SGD","BK4551","LU1435385759.SGD","LU1244550494.USD","BK4585","LU1429558221.USD","BK4139","LU1244550577.SGD","BK4516","LU1162221912.USD","LU2326559502.SGD","BK4588","IE00BFXG1179.USD","BK4187","ROIV","BA","LHX","BK4007","BK4564","LU1244550221.USD"],"gpt_icon":1},{"id":"2483379835","title":"Defense Stocks Can Keep Falling as Uncertainty in Washington Mounts, Analyst Says -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2483379835","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483379835?lang=en_us&edition=fundamental","pubTime":"2024-11-15 21:52","pubTimestamp":1731678720,"startTime":"0","endTime":"0","summary":"Investors are wondering what is next for defense stocks after a swift two-day decline triggered by President-elect Donald Trump's initial efforts to prepare a new team to defend the nation. Citi analyst Jason Gursky says the pain likely isn't over.Defense shares have been weak since Trump's Tuesday nomination of Pete Hegseth to serve as the next defense secretary. That new was followed by a Reuters report that the new administration is planning significant turnover at the Defense Department.Other security-related appointments included Marco Rubio as secretary of state, Kristi Noem as homeland security secretary, and Michael Waltz as national security advisor.Given that enormous helping of uncertainty, shares of large defense contractors Lockheed Martin, General Dynamics, Northrop Grumman, and L3Harris Technologies fell 5.5% on average between Tuesday and Thursday. The iShares Aerospace & Defense ETF fell 1.9%.General Dynamics and L3Harris are the most popular on Wall Street, with 63% o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","LU1244550494.USD","BK4007","BK4588","BK4551","LU1435385759.SGD","IE00BFXG1179.USD","BK1215","03650","LU1244550577.SGD","LHX","BK4139","BK4211","WASH","BK4516","BK4564","LU1429558221.USD","LMT","LU1162221912.USD","BK4187","ROIV","BK4585","LU2326559502.SGD","LU1244550221.USD","BA"],"gpt_icon":1},{"id":"2483569748","title":"Roivant Sciences Price Target Maintained With a $18.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483569748","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483569748?lang=en_us&edition=fundamental","pubTime":"2024-11-14 03:10","pubTimestamp":1731525000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 14:10 ET (19:10 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"gpt_icon":0},{"id":"2483302832","title":"Trump Taps Musk, Ramaswamy to Lead a 'Department of Government Efficiency.' He Called It 'The Manhattan Project of Our Time.' -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2483302832","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483302832?lang=en_us&edition=fundamental","pubTime":"2024-11-14 01:27","pubTimestamp":1731518820,"startTime":"0","endTime":"0","summary":"President-elect Donald Trump announced Tuesday evening that Tesla CEO Elon Musk and former Republican presidential candidate Vivek Ramaswamy will lead what Trump calls the Department of Government Efficiency, or DOGE. The name is a reference to Dogecoin, a cryptocurrency Musk has talked about in the past.In a statement, Trump said: \"Together, these two wonderful Americans will pave the way for my Administration to dismantle Government Bureaucracy, slash excess regulations, cut wasteful expenditures, and restructure Federal Agencies.\" Trump said Musk and Ramaswamy will provide \"advice and guidance\" and partner with the White House and Office of Management & Budget, with the goal of creating a \"smaller government with more efficiency and less bureaucracy.\". It's important to note that a department can't be created without congressional approval. Without that, DOGE will be a department in name only and act more like a consulting firm.On Wednesday, Ramaswamy doubled down the message, writi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"95786ae96ca0b78ebf897fbc4fba2dfc","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1551013425.SGD","LU2213496289.HKD","LU2326559502.SGD","LU1548497426.USD","BK4533","BK4588","LU0056508442.USD","LU0348723411.USD","LU0820561818.USD","LU0964807845.USD","LU1861558580.USD","BK4099","LU2063271972.USD","BK4581","LU0719512351.SGD","BK4548","LU0943347566.SGD","LU2357305700.SGD","LU2023250330.USD","SG9999015986.USD","TSLA","IE00B1XK9C88.USD","LU0316494557.USD","LU0097036916.USD","LU0823414478.USD","BK4534","LU0082616367.USD","LU2249611893.SGD","LU0820561909.HKD","LU0198837287.USD","BK4574","LU1629891620.HKD","LU0234572021.USD","LU1852331112.SGD","TSLL","LU1145028129.USD","LU1861559042.SGD","LU0820562030.AUD","LU0466842654.USD","ROIV","LU0234570918.USD","LU2756315664.SGD","LU0053666078.USD","LU1720051017.SGD","BK4592","LU1861220033.SGD","LU1429558221.USD","BK4007","LU1861215975.USD"],"gpt_icon":1},{"id":"2483588720","title":"EXPLAINER-How Musk's US government efficiency panel might work","url":"https://stock-news.laohu8.com/highlight/detail?id=2483588720","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483588720?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:21","pubTimestamp":1731511311,"startTime":"0","endTime":"0","summary":"WASHINGTON, Nov 13  - Donald Trump has tasked Elon Musk with setting up a panel to streamline the U.S. government. Although the president-elect has said little about how this group would operate, Musk has previously set an ambitious goal of cutting $2 trillion of spending.   Here is how this new panel, which will be headed up by Musk, the world's richest person, and former Republican Presidential candidate Vivek Ramaswamy, might work.   WHAT DOES MUSK WANT TO CUT?Former President Ronald Reagan announced in February 1982 that he would form a group of private sector experts to recommend ways","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820561818.USD","LU2756315318.SGD","LU0097036916.USD","BK4007","LU0820562030.AUD","BK4534","LU2326559502.SGD","LU1861558580.USD","BK4592","SG9999015945.SGD","LU1548497426.USD","IE00B1XK9C88.USD","TSLA","BK4581","BK4548","BK4527","ROIV","LU1720051108.HKD","BK4574","BK4533","LU2756315664.SGD","BK4139","BK4588","BK4550","LU2023250330.USD","BK4585","LU0719512351.SGD","LU2249611893.SGD","LU1852331112.SGD","BK4551","LU1551013425.SGD","LU1839511570.USD","LU2087621335.USD","LU1861215975.USD","LU2602419157.SGD","LU1914381329.SGD","LU1551013342.USD","LU1720051017.SGD","IE00BSNM7G36.USD","LU1145028129.USD","LU0053666078.USD","LU0964807845.USD","SG9999015978.USD","LU2063271972.USD","BK4099","SG9999015952.SGD","LU2357305700.SGD","LU0348723411.USD","LU1629891620.HKD","LU0316494557.USD"],"gpt_icon":1},{"id":"2483924093","title":"TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483924093","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483924093?lang=en_us&edition=fundamental","pubTime":"2024-11-13 08:15","pubTimestamp":1731456927,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) yesterday. The company’s shares closed yesterday...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-roivant-sciences-roiv-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-roivant-sciences-roiv-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","TD","ROIV"],"gpt_icon":0},{"id":"2482707371","title":"Roivant Sciences Ltd reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482707371","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482707371?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:38","pubTimestamp":1731418734,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd reports results for the quarter ended September 30 - Earnings SummaryRoivant Sciences Ltd ROIV.OQ reported a quarterly adjusted loss of 31 cents per share for the quarter ended Se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ1I1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"gpt_icon":0},{"id":"2482470648","title":"Roivant Sciences' Fiscal Q2 Net Loss Narrows, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2482470648","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482470648?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:45","pubTimestamp":1731415518,"startTime":"0","endTime":"0","summary":"Roivant Sciences  reported a fiscal Q2 net loss Tuesday of $0.31 per diluted share, narrowing from a loss of $0.40 a year earlier.Analysts polled by Capital IQ expected a loss of $0.27.Net revenue for the quarter ended Sept. 30 was $4.5 million, up from $3.6 million a year earlier.Analysts surveyed by Capital IQ expected $45.9 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ROIV"],"gpt_icon":0},{"id":"2482570550","title":"Roivant Sciences Q2 2025 GAAP EPS $(0.31) Misses $(0.26) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482570550","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482570550?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:29","pubTimestamp":1731414585,"startTime":"0","endTime":"0","summary":"Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.26) by 19.23 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41897449/roivant-sciences-q2-2025-gaap-eps-0-31-misses-0-26-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences Q2 2025 GAAP EPS $(0.31) Misses $(0.26) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"gpt_icon":0},{"id":"2482038187","title":"Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482038187","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482038187?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"BASEL, Switzerland and LONDON and NEW YORK, Nov. 12, 2024  -- Roivant  today reported its financial results for the second quarter ended September 30, 2024, and provided a business update.Brepocitinib 52-week data from the Phase 2 NEPTUNE study in non-infectious uveitis  showed potential best-in-indication efficacy sustained to one year; first patients enrolled in Phase 3 NIU program. IMVT-1402 cleared five Investigational New Drug  applications across a range of therapeutic areas and FDA divisions, including the potentially registrational trial for difficult-to-treat rheumatoid arthritis  expected to initiate by March 31, 2025. Batoclimab proof of concept data in Graves’ disease  demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs ; initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year end. Roivant continued to return capital through share","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R35Zaer8vgFzoWKpttvTXg--~B/aD00MDA7dz0xNzI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/96e32f55c54dad2fb7c9058f4f7181f9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R35Zaer8vgFzoWKpttvTXg--~B/aD00MDA7dz0xNzI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/96e32f55c54dad2fb7c9058f4f7181f9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roivant-reports-financial-results-second-120000604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LU0170899867.USD","BK4558","BK4161","LU1989772840.SGD","GD","ROIV","PH","BK4516","LU0070302665.USD","BK4139","LU0211331839.USD","BK4588","BK4550","LU0256863902.USD","LU0208291251.USD","LU1989772923.USD","BK4585","BK4566","BK4580","BK4091","BK4555","BK4187","LU0320765489.SGD","LU0256863811.USD","LU0417517546.SGD","NIU"],"gpt_icon":1},{"id":"2481510894","title":"Roivant Sciences (ROIV) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2481510894","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481510894?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:31","pubTimestamp":1731072713,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares closed yesterday at ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-receives-a-buy-from-td-cowen-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-receives-a-buy-from-td-cowen-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV","BK4566","BK4585","COWN","TD","BK4127","BK4007","BK4139","BK4207"],"gpt_icon":0},{"id":"2481250656","title":"Organon: FDA Extends Vtama Atopic-Dermatitis Review to March","url":"https://stock-news.laohu8.com/highlight/detail?id=2481250656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481250656?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":"Organon said the Food and Drug Administration extended by three months its review of an application seeking expanded approval of the healthcare company's recently acquired skin-care cream Vtama.Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and clinical-study report from a long-term extension study.The Jersey City, N.J., company picked up Vtama as part of its acquisition of Dermavant Sciences from Roivant Sciences last month and had been expecting a green light in atopic dermatitis by the end of the year.Organon noted that the FDA, which approved Vtama as a treatment for plaque psoriasis in 2022, hasn't raised any concerns regarding the safety and efficacy of Vtama or any concerns regarding the approvability of the new indication.Organon said that as a result of the delay, it now expects Vtama to contribute about $125 million in revenue next year, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2065170008.USD","BK4588","LU2065169927.USD","LU2065171311.SGD","BK4007","BK4139","BK4559","LU2065171402.SGD","ROIV","OGN"],"gpt_icon":0},{"id":"2479155252","title":"Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479155252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479155252?lang=en_us&edition=fundamental","pubTime":"2024-10-30 04:35","pubTimestamp":1730234100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nTUA4HL26J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2479257540","title":"Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479257540","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479257540?lang=en_us&edition=fundamental","pubTime":"2024-10-30 04:35","pubTimestamp":1730234100,"startTime":"0","endTime":"0","summary":"BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024  -- Roivant  today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update.Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about potential share repurchase","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R35Zaer8vgFzoWKpttvTXg--~B/aD00MDA7dz0xNzI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/96e32f55c54dad2fb7c9058f4f7181f9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R35Zaer8vgFzoWKpttvTXg--~B/aD00MDA7dz0xNzI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/96e32f55c54dad2fb7c9058f4f7181f9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roivant-report-financial-results-second-203500707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2478861864","title":"Organon Finalizes Acquisition of Dermavant From Roivant","url":"https://stock-news.laohu8.com/highlight/detail?id=2478861864","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478861864?lang=en_us&edition=fundamental","pubTime":"2024-10-28 21:44","pubTimestamp":1730123047,"startTime":"0","endTime":"0","summary":"Organon  said Monday it finalized the acquisition of Dermavant Sciences from Roivant .Dermavant develops and commercializes treatments in the immuno-dermatology space, including Vtama, which was approved by the US Food and Drug Administration to treat plaque psoriasis in adults, Organon said.Price: 17.37, Change: +0.21, Percent Change: +1.22","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU2065170008.USD","BK4588","LU2065169927.USD","LU2065171311.SGD","BK4007","BK4139","BK4559","LU2065171402.SGD","ROIV","OGN"],"gpt_icon":0},{"id":"2478248529","title":"Organon completes acquisition of Dermavant","url":"https://stock-news.laohu8.com/highlight/detail?id=2478248529","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478248529?lang=en_us&edition=fundamental","pubTime":"2024-10-28 21:30","pubTimestamp":1730122259,"startTime":"0","endTime":"0","summary":"Organon (OGN) announced completion of its acquisition of Dermavant Sciencesfrom Roivant (ROIV). Dermavant is a company dedicated to developing and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/organon-completes-acquisition-of-dermavant?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/organon-completes-acquisition-of-dermavant?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065170008.USD","OGN","LU2065171402.SGD","ROIV","BK4007","BK4588","BK4585","BK4559","BK4139","LU2065171311.SGD","LU2065169927.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.roivant.com","stockEarnings":[{"period":"1week","weight":0.1165},{"period":"1month","weight":0.0453},{"period":"3month","weight":0.0515},{"period":"6month","weight":0.1612},{"period":"1year","weight":0.3647},{"period":"ytd","weight":0.1095}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.091624},{"month":2,"riseRate":0.25,"avgChangeRate":0.003027},{"month":3,"riseRate":0,"avgChangeRate":-0.105559},{"month":4,"riseRate":0.75,"avgChangeRate":-0.013041},{"month":5,"riseRate":0.5,"avgChangeRate":0.053964},{"month":6,"riseRate":0.75,"avgChangeRate":0.012477},{"month":7,"riseRate":0.75,"avgChangeRate":0.048723},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002132},{"month":9,"riseRate":0.25,"avgChangeRate":-0.05068},{"month":10,"riseRate":0.5,"avgChangeRate":0.046516},{"month":11,"riseRate":0.75,"avgChangeRate":0.015771},{"month":12,"riseRate":1,"avgChangeRate":0.39524}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}